Project Grant CLSS00000062621

This federal Project Grant award of $75,500,157, funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program, is focused on addressing the opioid crisis in the District of Columbia. The grant, titled "DCOR 4 - The District of Columbia's Opioid Response 4 (DCOR 4) Initiative," aims to increase access to medication for opioid use disorder...

The Louisiana Department of Health (LDH), through its Office of Behavioral Health (OBH) Division, has been awarded a $54,004,380 Project Grant by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Opioid State Targeted Response (Opioid STR) program (CFDA 93.788). This 3-year grant, titled "Louisiana State Opioid Response (LASOR) 4.0," aims to enhance existing statewide prevention, treatment, and recovery support services for individuals with or at risk for...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,398,820.00 to fund research aimed at developing safer opioid analgesics and antagonists with the goal of reducing the adverse effects associated with traditional opioid medications. The key products and services to be delivered under this grant include: Synthesis and in vitro characterization of novel opioid receptor ligands that...

The Department of Justice, Office of Justice Programs, Bureau of Justice Assistance awarded a $1,600,000 Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838) Project Grant to the Southern Nevada Health District (SNHD) and sub-recipients Las Vegas Metropolitan Police Department (LVMPD) and University of Nevada, Las Vegas (UNLV). The grant will fund a collaborative initiative to address the opioid crisis in Clark County, Nevada through a public health-focused overdose...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to modify the Opioid Use Disorder (OUD) Cascade of Care model to better reflect the changing landscape of real-world OUD treatment. The $459,045 grant, awarded on September 30, 2024, will enable the prime awardee, the RAND Corporation, to link data from healthcare, substance use treatment, prescription drug monitoring, and mortality systems...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $220,668 to Amalgent Therapeutics, Inc. to support the development of a novel opioid adjuvant. The adjuvant is designed to increase the pain-relieving efficacy of opioid medications, allowing for reduced opioid dosing and mitigating the risks of opioid abuse, dependence, and tolerance. The award funds two specific aims: 1) investigating the...

The Oglala Lakota Division of Behavioral Health (OL-DBH) was awarded a $1,500,000 Project Grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) Tribal Opioid Response (SAMHSA TOR) program (CFDA 93.243, Substance Abuse and Mental Health Services Projects of Regional and National Significance). The grant funding will be used to continue implementing five key interventions to address prescription and illicit opioid and psychostimulant abuse on the Pine Ridge...

The Healing In The Hood Inc. organization was awarded a $125,000 annual Project Grant under the Drug-Free Communities (DFC) Support Program (CFDA 93.276) from the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention (CDC). This five-year grant, with an award date of September 30, 2024 and an ultimate completion date of September 29, 2029, will enable the organization to lead the Opioid Prescription Drug and Synthetics (O.P.P.S.) Coalition. The...

The federal Project Grant award, totaling $398,137.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding supports the development of high-precision epigenetic therapeutics for opioid use disorder (OUD), a growing epidemic in the United States. The project aims to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression under chronic opioid exposure, and to test the efficacy...

The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $267,000 Project Grant (R21DA058120) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop novel depot formulations for the on-demand, tamper- and diversion-proof delivery of opioids. The project aims to create injectable depot formulations made of polymers covalently linked to opioids via photolabile linkers. This approach would...